Global Information
회사소개 | 문의 | 위시리스트

유럽 28개국의 암진단 시장 : 매출액 예측과 공급업체 점유율(암유전자, 생화학적 마커, 림포카인, 증식인자/GF, 콜로니자극인자/CSF, 면역조직화학염색), 경쟁 전략, 혁신 기술

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

리서치사 Venture Planning Group
발행일 상품 코드 352212
페이지 정보 영문 925 Pages
가격
US $ 34,500 ₩ 42,286,000 DataPack (Local license)
US $ 43,500 ₩ 53,317,000 PDF by E-mail (Local license)
US $ 74,900 ₩ 91,804,000 DataPack (Global license)
US $ 94,300 ₩ 115,583,000 PDF by E-mail (Global license)


유럽 28개국의 암진단 시장 : 매출액 예측과 공급업체 점유율(암유전자, 생화학적 마커, 림포카인, 증식인자/GF, 콜로니자극인자/CSF, 면역조직화학염색), 경쟁 전략, 혁신 기술 2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains
발행일 : 페이지 정보 : 영문 925 Pages

유럽 28개국의 암진단 시장에 대해 조사분석했으며, 부문별 시장 분석, 종양마커 예측, 주요 공급업체, 신규 진출 기업, 혁신 기술과 제품, 기존·신규 검사 방법, 기존 검사 장비, 신규 기술, 고유 기회와 공급업체의 성장 전략 등에 대한 체계적인 정보를 정리하여 전해드립니다.

제1장 서론

제2장 세계 시장 개요

제3장 주요 제품 개발 기회

  • 시약 키트와 검사 시스템/패널
  • 검사 장비
  • 컴퓨터, 소프트웨어, 자동화
  • 보조 장비

제4장 분산형 검사 제품의 설계 기준

제5장 대체적 시장 침투 전략

  • 내부 개발
  • 협업 협정
  • 대학과의 계약
  • 유통 전략

제6장 잠재적 시장 진출 장벽과 리스크

  • 시장 성숙도
  • 비용 억제
  • 경쟁
  • 기술면에서의 우위성과 한계
  • 특허권 보호
  • 규제상 제약
  • 분산형 검사 시장이 해결해야 할 과제

제7장 세계 시장과 기술 개요

  • 암 통계와 병인
    • 유방암
    • 폐암
    • 결장·직장암
    • 전립선암
    • 위암
    • 백혈병
    • 림프종
    • 구강암
    • 피부암
    • 자궁암
    • 난소암
    • 방광암
  • 기존·신규 암진단 검사
  • 검사 장비 리뷰와 시장의 요구
  • 기존·신규 암진단 기술
  • 개인용 검사

제8장 국가별 시장 분석 : 검사건수와 매출액 예측, 공급업체 점유율

  • 오스트리아
  • 벨기에
  • 불가리아
  • 체코
  • 덴마크
  • 에스토니아
  • 핀란드
  • 프랑스
  • 독일
  • 그리스
  • 헝가리
  • 아이슬란드
  • 아일랜드
  • 이탈리아
  • 라트비아
  • 리투아니아
  • 몰타
  • 네덜란드
  • 노르웨이
  • 폴란드
  • 포르투갈
  • 루마니아
  • 슬로바키아
  • 슬로베니아
  • 스페인
  • 스웨덴
  • 스위스
  • 영국

제9장 경쟁사 개요

  • Abbott
  • AdnaGen/Alere
  • Agilent Technologies
  • Applied Gene Technologies
  • Arca Biopharma
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biomedical Diagnostics
  • bioMerieux
  • Bio-Rad
  • CellSearch
  • Cepheid
  • Correlogic Systems/Vermillion
  • Decode Genetics
  • Diadexus
  • Diagnocure
  • Diasorin
  • Eiken Chemical
  • Elitech Group
  • Enterix
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • Fujirebio
  • Guided Therapeutics
  • Hologic/Gen-Probe
  • Kreatech/Leica
  • Kyowa Medex
  • Mackay Life Sciences
  • Myriad Genetics
  • OncoLab
  • Ortho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen
  • Quest Diagnostics
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • Takara Bio
  • Targeted Diagnostics & Therapeutics
  • Tosoh
  • Thermo
  • Veridex
  • Wako Pure Chemicals
  • Wallac/PE
  • Zila

제10장 부록

도표

KSA 16.02.24

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

This new 28-country survey from VPGMarketResearch.com contains over 925 pages and 366 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Geographic Coverage

Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Tests

- Oncogenes - Biochemical Markers - Growth Factors - Colony Stimulating Factors - Hormones - Immunohistochemical Stains - Lymphokines

- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product suppliers in major countries by individual test

- Five-year test volume and sales forecasts for major cancer diagnostic assays.

Instrumentation Review

- Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

- Assessment of latest technologies and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies.

- Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

- Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

- The companies analyzed in the report include:   

   - Abbott
   - AdnaGen/Alere
   - Agilent Technologies
   - Applied Gene Technologies
   - Arca Biopharma
   - Beckman Coulter/Danaher
   - Becton Dickinson
   - Biomedical Diagnostics/Theradiag
   - bioMerieux
   - Bio-Rad
   - CellSearch
   - Cepheid
   - Correlogic Systems/Vermillion
   - Decode Genetics
   - Diadexus
   - Diagnocure
   - DiaSorin
   - Eiken Chemical
   - Elitech Group
   - Enterix/Clinical Genomics
   - Enzo Biochem
   - Epigenomics
   - Exact Sciences
   - Fujirebio
   - Guided Therapeutics
   - Hologic/Gen-Probe
   - Kreatech/Leica
   - Kyowa Medex
   - Mackay Life Sciences
   - Myriad Genetics
   - OncoLab
   - Ortho-Clinical Diagnostics
   - Panacea Pharmaceuticals
   - Polartechnics
   - Polymedco
   - PreMD
   - Qiagen
   - Quest Diagnostics
   - Radient Pharmaceuticals
   - Roche
   - Scienion
   - Sequenom
   - Siemens Healthcare
   - Takara Bio
   - Targeted Diagnostics & Therapeutics
   - Thermo Fisher/Affymetrix
   - Tosoh
   - Veridex
   - Wako Pure Chemicals
   - Wallac/PE
   - Zilla/Alere

Contains 925 pages and 366 tables.

Table of Contents

I. Introduction

II. Worldwide Market Overview

III. Major Product Development Opportunities

  • A. Reagent Kits and Test Systems/Panels
  • B. Instrumentation
  • C. Computers, Software and Automation
  • D. Auxiliary Products

IV. Design Criteria for Decentralized Testing Products

V. Alternative Market Penetration Strategies

  • A. Internal Development
  • B. Collaborative Arrangements
  • C. University Contracts
  • D. Distribution Strategies

VI. Potential Market Entry Barriers and Risks

  • A. Market Maturity
  • B. Cost Containment
  • C. Competition
  • D. Technological Edge and Limitations
  • E. Patent Protection
  • F. Regulatory Constraints
  • G. Decentralized Testing Market Challenges

VII. Worldwide Market and Technology Overview

  • A. Cancer Statistics and Etiology
    • 1. Breast Cancer
    • 2. Lung Cancer
    • 3. Colon and Rectum Cancer
    • 4. Prostate Cancer
    • 5. Stomach Cancer
    • 6. Leukemia
    • 7. Lymphoma
    • 8. Oral Cancer
    • 9. Skin Cancer
    • 10. Uterine Cancer
    • 11. Ovarian Cancer
    • 12. Bladder Cancer
  • B. Major Current and Emerging Cancer Diagnostic Tests
    • 1. Introduction
    • 2. Tumor Marker Classification
    • 3. ACTH
    • 4. Alpha-Fetoprotein (AFP)
    • 5. Beta-2 Microglobulin
    • 6. CA 15-3/27.29
    • 7. CA 19-9
    • 8. CA-125
    • 9. Calcitonin
    • 10. Carcinoembrionic Antigen (CEA)
    • 11. Estrogen and Progesterone Receptors
    • 12. Ferritin
    • 13. Gastrin
    • 14. Human Chorionic Gonadotropin (HCG)
    • 15. Insulin
    • 16. NSE
    • 17. Occult Blood
    • 18. PAP Smear/HPV
    • 19. Prostatic Acid Phosphatase (PAP)
    • 20. Prostate-Specific Antigen (PSA)
    • 21. Squamous Cell Carcinoma Antigen (SCC)
    • 22. T and B Lymphocytes
    • 23. TdT
    • 24. Thyroglobulin
    • 25. Tissue Polypeptide Antigen (TPA)
    • 26. Biochemical Tumor Markers
    • 27. Oncogenes
      • Abl/abl-bcr
      • AIB1
      • BCL-2
      • BRCA1
      • CD44
      • C-fos
      • C-myb
      • C-myc
      • CYP-17
      • Erb-B
      • HPC1
      • N-myc
      • P40
      • P51
      • P53
      • PIK3CA
      • PTI-1
      • Ras
      • Reg
      • Sis
      • Src
    • 28. Polypeptide Growth Factors
      • Basic Fibroblast Growth Factor
      • Beta-TGF
      • Cachectin (TNT)
      • Calmodulin
      • ECFR
      • Nerve Growth Factor (NGF)
      • Epidermal Growth Factor (EGF)
      • Ornithine Decarboxylase
      • Transferrin
      • Transforming Growth Factor-Alpha
    • 29. Ectopic Hormones
    • 30. Colony Stimulating Factors
    • 31. Lymphokines
      • Alpha-Interferon
      • B Cell Growth Factors
      • B Cell Growth Factor (BCGF)
      • Gamma-Interferon
      • Interleukin-1 (IL-1)
      • Macrophage Activating Factor
    • 32. Immunohistochemical Stains
    • 33. Emerging Tumor Markers
      • N-Acetylglucosamine
      • Actin
      • Alpha-Actin
      • Antineuronal Antibodies
      • 7B2
      • B72.3
      • Bax
      • BCD-F9
      • BLCA-4
      • Blood Group Antigens A,B,H
      • CA 50
      • CA 72-4/TAG-72
      • CA 195
      • CA-242
      • CA-549
      • CAM 26
      • CAR-3
      • Cathepsin-D
      • Chromogranin A and B
      • Cluster 1 Antigen
      • Cluster-5/5A Antigen
      • CTA
      • CU18
      • DR-70
      • DU-PAN-2
      • Endometrial Bleeding Associated Factor
      • Endostatin
      • Epithelial Membrane Antigen
      • Feulgen Hydrolysis
      • Fibronectin
      • FSH
      • (1->3)-L-fucosyltransferase
      • Gastrin-Releasing Peptide (GRP)
      • GDCFP-15
      • Glucagon
      • Glycoamines
      • H23
      • Her-2
      • Human Carcinoma Antigen
      • HPA
      • HSP27
      • Intermediate Filaments
      • Cytokeratins/CK18/Cyfra 21-1
      • Desmin
      • Gliofibrillary Acid Protein
      • Neurofilaments
      • Vimentin
      • KA 93
      • Kinases
      • KP16D3
      • LAI
      • Leukocyte Common Antigen
      • Lewis Antigens
      • Lysophosphatidic Acid (LPA)
      • Ma 695/Ma 552
      • MABDF3
      • MAG
      • ME1
      • Minactivin
      • MN/CA9
      • MSA
      • Mucin Cancer Antigen (MCA)
      • Multiple Tumor Suppressor 1
      • Myosin
      • NEA-130
      • NMP22
      • OA-519
      • Opioid Peptides
      • P-glycoprotein
      • Pancreatic Oncofetal Antigen (POA)
      • Placental Lactogen
      • PR92
      • Proliferative Index, Ki-67
      • Px
      • RB Inactivation/Deletion
      • Ret
      • SCCL 175
      • Selectin
      • Sialic Acid
      • Sialyl SSEA-1/SLX
      • SN10
      • Somatostatin
      • TA-90
      • TABA
      • Tachykinin
      • TAG 12
      • TPS
      • Troponin
      • Tubulin
      • VCAM
      • VEGF
      • Villen
  • C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
  • D. Current and Emerging Cancer Diagnostic Technologies
    • 1. Monoclonal and Polyclonal Antibodies
    • 2. Immunoassays
    • 3. Molecular Diagnostics
    • 4. Chromosome Analysis
      • a. Chronic Myelogenous Leukemia (CML)
      • b. Acute Myeloid Leukemia (AML)
      • c. Acute Lymphoblastic Leukemia (ALL)
      • d. Malignant Lymphomas Lymphoid Malignancies
      • e. Chronic Lymphocytic Leukemia (CLL)
      • f. Solid Cancers
      • g. Chromosomal Translocation and Oncogenes
    • 5. Artificial Intelligence
    • 6. Flow Cytometry
    • 7. Two Dimensional Gel Electrophoresis (2-DGE)
    • 8. Biosensors
    • 9. Competing/Complementing Technologies
  • E. Personal Testing

VIII. Country Market Analyses: Test Volume and Sales Forecasts, Supplier Shares

  • Austria
  • Belgium
  • Bulgaria
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • UK

IX. Competitive Profiles

  • Abbott
  • AdnaGen/Alere
  • Agilent Technologies
  • Applied Gene Technologies
  • Arca Biopharma
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biomedical Diagnostics
  • bioMerieux
  • Bio-Rad
  • CellSearch
  • Cepheid
  • Correlogic Systems/Vermillion
  • Decode Genetics
  • Diadexus
  • Diagnocure
  • Diasorin
  • Eiken Chemical
  • Elitech Group
  • Enterix
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • Fujirebio
  • Guided Therapeutics
  • Hologic/Gen-Probe
  • Kreatech/Leica
  • Kyowa Medex
  • Mackay Life Sciences
  • Myriad Genetics
  • OncoLab
  • Ortho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen
  • Quest Diagnostics
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • Takara Bio
  • Targeted Diagnostics & Therapeutics
  • Tosoh
  • Thermo
  • Veridex
  • Wako Pure Chemicals
  • Wallac/PE
  • Zila

X. Appendix: Major Universities and Research Centers Developing Cancer Diagnostic Technologies and Applications

List of Tables

  • Austria Cancer Diagnostic Volume Forecasts by Test
  • Austria Cancer Diagnostics Sales Forecasts by Test
  • Belgium Cancer Diagnostic Volume Forecasts by Test
  • Belgium Cancer Diagnostics Sales Forecasts by Test
  • Bulgaria Cancer Diagnostic Volume Forecasts by Test
  • Bulgaria Cancer Diagnostics Sales Forecasts by Test
  • Czech Republic Cancer Diagnostic Volume Forecasts by Test
  • Czech Republic Cancer Diagnostics Sales Forecasts by Test
  • Denmark Cancer Diagnostic Volume Forecasts by Test
  • Denmark Cancer Diagnostics Sales Forecasts by Test
  • Estonia Cancer Diagnostic Volume Forecasts by Test
  • Estonia Cancer Diagnostics Sales Forecasts by Test
  • Finland Cancer Diagnostic Volume Forecasts by Test
  • Finland Cancer Diagnostics Sales Forecasts by Test
  • France Executive Summary Table:
  • Total Cancer Diagnostic Test Volume and
  • Sales Forecast by Market Segment
  • France, Estimated Cancer Death Rates
  • Per 100,000 Population
  • France, Laboratories Performing Tumor
  • Marker Tests by Market Segment
  • France, Hospital Laboratories Performing
  • Tumor Marker Tests by Bed Size
  • France, Commercial/Private Laboratories
  • Performing Tumor Markers by Annual Test Volume
  • France, Total Tumor Marker Test Volume
  • Forecast by Market Segment
  • France, All Market Segments Major Tumor
  • Marker Test Volume Forecast
  • France, Hospital Laboratories Major Tumor
  • Marker Test Volume Forecast by Test
  • France, Commercial/Private Laboratories
  • Marker Test Volume Forecast
  • France, Total Tumor Marker Sales Major Tumor
  • Forecast by Market Segment
  • France, All Market Segments Major Tumor
  • Marker Sales Forecast by Test
  • France, Hospital Laboratories Major Tumor
  • Marker Sales Forecast by Test
  • France, Commercial/Private Laboratories Cancer
  • Diagnostics Market Forecast by Test
  • France, ACTH Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • France, AFP Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • France, Beta-2 Microglobulin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, CA 15-3/27.29 Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, CA 19-9 Test Volume and Diagnostics
  • Sales Forecast by Market
  • France, CA-125 Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • France, Calcitonin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • France, Cathepsin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • France, CEA Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • France, Colon-Specific Antigen Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Cytokeratins Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Estrogen Receptor Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Ferritin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Gastrin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, HCG Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • France, Insulin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Interferons Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Interleukins Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Lymphocyte Subtyping Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, NSE Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • France, Nucleolar Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • France, Occult Blood Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Oncogenes Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Pancreatic Oncofetal Antigen
  • Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • France, PAP Smear Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Parathyroid Hormone Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Progesterone Receptor Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, PAP Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • France, PSA Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • France, S-100 Protein Test Volume and Sales
  • Diagnostics Sales Forecast by Market Segment
  • France, Serotonin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Sialic Acid Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Squamous Cell Carcinoma Antigen
  • Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • France, TDT Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • France, Thymidine Kinase Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, Thyroglobulin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • France, TPA Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • France, Total Tumor Marker
  • Sales by Major Suppliers
  • France, AFP Testing Market Diagnostics
  • Sales by Major Supplier
  • France, CA 15-3 Testing Market Diagnostics
  • Sales by Major Supplier
  • France, CA 19-9 Testing Market Diagnostics
  • Sales by Major Supplier
  • France, CA 125 Testing Market Diagnostics
  • Sales by Major Supplier
  • France, CEA Testing Market Diagnostics
  • Sales by Major Supplier
  • France, NSE Testing Market Diagnostics
  • Sales by Major Supplier
  • France, PAP Testing Market Diagnostics
  • Sales by Major Supplier
  • France, PSA Testing Market Diagnostics
  • Sales by Major Supplier
  • Germany Executive Summary Table: Total
  • Tumor Marker Test Volume and Sales
  • Forecast by Market Segment
  • Germany, Estimated Cancer Death Rates
  • Per 100,000 Population
  • Germany, Laboratories Performing Tumor
  • Marker Tests by Market Segment
  • Germany, Hospital Laboratories Performing
  • Tumor Marker Tests by Bed Size
  • Germany, Commercial/Private Laboratories
  • Performing Tumor Markers by Annual Test Volume
  • Germany, Total Tumor Marker Test Volume
  • Forecast by Market Segment
  • Germany, All Market Segments, Major Tumor
  • Marker Test Volume Forecast
  • Germany, Hospital Laboratories, Major
  • Tumor Marker Test Volume Forecast by Test
  • Germany, Commercial/Private Laboratories
  • Major Tumor Marker Test Volume Forecast
  • Germany, Physician Offices/Group
  • Practices Major Tumor Marker
  • Test Volume Forecast
  • Germany, Total Tumor Marker Sales
  • Forecast by Market Segment
  • Germany, All Market Segments Major Tumor
  • Marker Sales Forecast by Test
  • Germany, Hospital Laboratories, Major Tumor
  • Marker Sales Forecast by Test
  • Germany, Commercial/Private Laboratories
  • Major Tumor Marker Sales Forecast by Test
  • Germany, Physician Offices/Group Practices
  • Major Tumor Marker Sales Forecast by Test
  • Germany, ACTH Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, AFP Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, Beta-2 Microglobulin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, CA-15-3/27.29 Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, CA-19 Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, CA 125 Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, Calcitonin Test Volume and
  • Diagnostic Sales Forecast by Market Segment
  • Germany, Cathepsin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, CEA Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Germany, Chromogranin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Colon-Specific Antigen Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Cytokeratins Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Estrogen Receptor Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Ferritin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, Gastrin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, HCG, Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, Insulin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, Interferons Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Interleukins Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Lymphocyte Subtyping Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, NSE Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, Occult Blood Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Oncogenes Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Pancreatic Oncofetal Antigen
  • Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Germany, Pap Smear Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Parathyroid Hormone Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Progesterone Receptor Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, PAP Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, PSA Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, S-100 Protein Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Serotonin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Sialic Acid Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Squamous Cell Carcinoma Antigen
  • Test Volume and Diagnostics Sales Forecast
  • by Market Segment
  • Germany, TDT Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, Thymidine Kinase Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, Thyroglobulin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Germany, TPA Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Germany, Total Tumor Marker Sales
  • by Major Supplier
  • Germany, AFP Testing Market Diagnostics
  • Sales by Major Supplier
  • Germany CA 15-3/27.29 Testing Market
  • Diagnostics Sales by Major Supplier
  • Germany CA 19-9 Testing Market Diagnostics
  • Sales by Major Supplier
  • Germany, CA 125 Testing Market Diagnostics
  • Sales by Major Supplier
  • Germany, CEA Testing Market Diagnostics
  • Sales by Major Supplier
  • Germany, PSA Testing Market Diagnostics
  • Sales by Major Supplier
  • Greece Cancer Diagnostic Volume Forecasts by Test
  • Greece Cancer Diagnostics Sales Forecasts by Test
  • Hungary Cancer Diagnostic Volume Forecasts by Test
  • Hungary Cancer Diagnostics Sales Forecasts by Test
  • Iceland Cancer Diagnostic Volume Forecasts by Test
  • Iceland Cancer Diagnostics Sales Forecasts by Test
  • Ireland Cancer Diagnostic Volume Forecasts by Test
  • Ireland Cancer Diagnostics Sales Forecasts by Test
  • Italy Executive Summary Table: Total Tumor
  • Marker Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Italy, Estimated Cancer Death Rates
  • Per 100,000 Population
  • Italy, Laboratories Performing Tumor
  • Marker Tests by Market Segment
  • Italy, Hospital Laboratories Performing
  • Tumor Marker Tests by Bed Size
  • Italy, Commercial/Private Laboratories
  • Performing Tumor Markers by Annual
  • Test Volume
  • Italy, Total Tumor Marker Test Volume
  • Forecast by Market Segment
  • Italy, All Market Segments Major Cancer
  • Diagnostic Test Volume Forecast
  • Italy, Hospital Laboratories Major Tumor
  • Marker Test Volume Forecast
  • Italy, Commercial/Private Laboratories
  • Major Tumor Marker Test Volume Forecast
  • Italy, Total Tumor Marker Test Market
  • Forecast by Market Segment
  • Italy, All Market Segments Major Tumor
  • Marker Sales Forecast by Test
  • Italy, Hospital Laboratories Major
  • Tumor Marker Forecast by Test
  • Italy, Commercial/Private Laboratories
  • Major Tumor Marker Sales Forecast by Test
  • Italy, ACTH Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Italy, AFP Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Italy, Beta-2 Microglobulin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Italy, CA 15-3/27.29 Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Italy, CA-19-9 Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Italy, CA 125 Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Italy, Calcitonin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Italy, CEA Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Italy, Chromogranin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Italy, Colon Specific Antigen Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Italy, Cytokeratins Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Italy, Estrogen Receptor Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Italy, Ferritin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Italy, Gastrin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Italy, HCG Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Italy, Insulin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Italy, Lymphocyte Subtyping Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Italy, NSE Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Italy, Occult Blood Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Italy, Oncogenes Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Italy, Pancreatic Oncofetal Antigen Test
  • Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Italy, PAP Smear Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Italy, Parathyroid Hormone Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Italy, Progesterone Receptor Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Italy, PAP Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Italy, PSA Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Italy, S-100 Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Italy, Serotonin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Italy, Sialic Acid Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Italy, Squamous Cell Carcinoma Antigen Test
  • Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Italy, TDT Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Italy, Thymidine Kinase Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Italy, Thyroglobulin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Italy, TPA Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Italy, Total Tumor Markers
  • Sales by Major Suppliers
  • Italy, AFP Testing Market Diagnostics
  • Sales by Major Supplier
  • Italy, CEA Testing Market Diagnostics
  • Sales by Major Supplier
  • Italy, PSA Testing Market Diagnostics
  • Sales by Major Supplier
  • Latvia Cancer Diagnostic Volume Forecasts by Test
  • Latvia Cancer Diagnostics Sales Forecasts by Test
  • Lithuania Cancer Diagnostic Volume Forecasts by Test
  • Lithuania Cancer Diagnostics Sales Forecasts by Test
  • Malta Cancer Diagnostic Volume Forecasts by Test
  • Malta Cancer Diagnostics Sales Forecasts by Test
  • Netherlands Cancer Diagnostic Volume Forecasts by Test
  • Netherlands Cancer Diagnostics Sales Forecasts by Test
  • Norway Cancer Diagnostic Volume Forecasts by Test
  • Norway Cancer Diagnostics Sales Forecasts by Test
  • Poland Cancer Diagnostic Volume Forecasts by Test
  • Poland Cancer Diagnostics Sales Forecasts by Test
  • Portugal Cancer Diagnostic Volume Forecasts by Test
  • Portugal Cancer Diagnostics Sales Forecasts by Test
  • Romania Cancer Diagnostic Volume Forecasts by Test
  • Romania Cancer Diagnostics Sales Forecasts by Test
  • Slovakia Cancer Diagnostic Volume Forecasts by Test
  • Slovakia Cancer Diagnostics Sales Forecasts by Test
  • Slovenia Cancer Diagnostic Volume Forecasts by Test
  • Slovenia Cancer Diagnostics Sales Forecasts by Test
  • Spain Executive Summary Table: Total
  • Tumor Marker Test Volume and Sales
  • Forecast by Market Segment
  • Spain, Estimated Cancer Death Rates
  • Per 100,000 Population
  • Spain, Laboratories Performing Tumor
  • Marker Tests by Market Segment
  • Spain, Hospital Laboratories Performing
  • Tumor Marker Tests by Bed Size
  • Spain, Commercial/Private Laboratories
  • Performing Tumor Markers by
  • Annual Test Volume
  • Spain, Total Tumor Marker Test Volume
  • Forecast by Market Segment
  • Spain, All Market Segment Major Cancer
  • Diagnostic Test Volume Forecast
  • Spain, Hospital Laboratories Major Cancer
  • Diagnostic Test Volume Forecast by Test
  • Spain, Commercial/Private Laboratories
  • Major Tumor Marker Test Volume Forecast
  • Spain, Total Tumor Marker Sales
  • Forecast by Market Segment
  • Spain, All Market Segments Major Tumor
  • Marker Sales Forecast by Test
  • Spain, Hospital Laboratories Major Tumor
  • Marker Sales Forecast by Test
  • Spain, Commercial/Private Laboratories Major
  • Tumor Marker Sales Forecast by Test
  • Spain, AFP Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Spain, Beta-2 Microglobulin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Spain, CA 15-3 Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, CA 19-9 Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, CA-125 Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, Calcitonin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, CEA Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Spain, Colon-Specific Antigen Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Spain, Estrogen Receptor Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Spain, Ferritin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, Gastrin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, HCG Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, Insulin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, Lymphocyte Subtyping
  • Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, NSE Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, Occult Blood Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Spain, Oncogenes Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Spain, Pancreatic Oncofetal Antigen
  • Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, PAP Smear Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Spain, Parathyroid Hormone Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Spain, Progesterone Receptor
  • Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Spain, PAP Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, PSA Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, S-100 Protein Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Spain, Serotonin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Spain, Sialic Acid Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • Spain, Squamous Cell Carcinoma Antigen
  • Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • Spain, TDT Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, Thymidine Kinase
  • Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, Thyroglobulin
  • Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, TPA Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • Spain, Total Tumor Marker Sales
  • by Major Suppliers
  • Spain, AFP Testing Market Diagnostics
  • Sales by Major Supplier
  • Spain, CA 15-3/27.29 Testing Market
  • Diagnostics Sales by Major Supplier
  • Spain, 19-9 Testing Market Diagnostics
  • Sales by Major Supplier
  • Spain, CA 125 Testing Market Diagnostics
  • Sales by Major Supplier
  • Spain, CEA Testing Market Diagnostics
  • Sales by Major Supplier
  • Spain, PSA Testing Market Diagnostics
  • Sales by Major Supplier
  • Sweden Cancer Diagnostic Volume Forecasts by Test
  • Sweden Cancer Diagnostics Sales Forecasts by Test
  • Switzerland Cancer Diagnostic Volume Forecasts by Test
  • Switzerland Cancer Diagnostics Sales Forecasts by Test
  • U.K. Executive Summary Table: Total
  • Tumor Marker Test Volume and Sales
  • Forecast by Market Segment
  • U.K., Estimated Cancer Death Rates
  • Per 100,000 Population
  • U.K., Laboratories Performing Tumor
  • Marker Tests by Market Segment
  • U.K., Hospital Laboratories Performing
  • Tumor Marker Tests by Bed Size
  • U.K., Commercial/Private Laboratories
  • Performing Tumor Marker Tests by
  • Annual Test Volume
  • U.K., Total Tumor Marker Testing Volume
  • Forecast by Market Segment
  • U.K., All Market Segments Major
  • Tumor Marker Test Volume Forecast
  • U.K., Hospital Laboratories Major
  • Tumor Marker Test Volume
  • Forecast by Test
  • U.K., Commercial/Private Laboratories
  • Major Tumor Marker Test Volume Forecast
  • U.K., Total Tumor Marker Sales
  • Forecast by Market Segment
  • U.K., All Market Segments Major
  • Tumor Marker Sales Forecast by Test
  • U.K., Hospital Laboratories Major
  • Tumor Marker Sales Forecast by Test
  • U.K., Commercial/Private Laboratories
  • Major Tumor Marker Sales Forecast by Test
  • U.K., ACTH Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • U.K., AFP Test Volume and Diagnostics Sales
  • Forecast by Market Segment
  • U.K., Beta-2 Microglobulin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • U.K., CA 15-3/27.29 Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • U.K., CA 19-9 Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., CA-125 Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., Calcitonin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • U.K., CEA Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., Chromogranin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., Colon-Specific Antigen Test Volume
  • and Diagnostics Sales by Market Segment
  • U.K., Cytokeratins Test Volume and
  • Diagnostics Sales Forecast
  • by Market Segment
  • U.K., Estrogen Receptor Test Volume and
  • Diagnostics Sales Forecast
  • by Market Segment
  • U.K., Ferritin Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • U.K., Gastrin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., HCG Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., Insulin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., Lymphocyte Subtyping Test Volume and
  • Diagnostics Sales Forecast
  • by Market Segment
  • U.K., NSE Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., Occult Blood Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • U.K., Oncogenes Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • U.K., Pancreatic Oncofetal Antigen
  • Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., PAP Smear Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., Parathyroid Hormone
  • Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., Progesterone Receptor
  • Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., PAP Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., PSA Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., S-100 Protein Test Volume and
  • Diagnostics Sales Forecast by Market Segment
  • U.K., Serotonin Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., Sialic Acid Test Volume and
  • Diagnostics Sales Forecast
  • by Market Segment
  • U.K., Squamous Cell Carcinoma Antigen
  • Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., TDT Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., Thymidine Kinase
  • Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., Thyroglobulin
  • Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., TPA Test Volume and Diagnostics
  • Sales Forecast by Market Segment
  • U.K., Total Tumor Marker Sales and
  • Market Shares Forecast
  • U.K., CEA Testing Market Diagnostics
  • Sales by Major Supplier
  • U.K., PSA Testing Market Diagnostics
  • Sales by Major Supplier
  • Tumor Marker Classification
  • Major Companies Developing or
  • Marketing ACTH Tests
  • Major Companies Developing or
  • Marketing AFP Tests
  • Major Companies Developing or
  • Marketing Beta-2 Microglobulin Tests
  • Major Companies Developing or
  • Marketing CA 15-3/27.29 Tests
  • Major Companies Developing or
  • Marketing CA 19-9 Tests
  • Major Companies Developing or
  • Marketing CA 125 Tests
  • Major Companies Developing or
  • Marketing Calcitonin Tests
  • Major Companies Developing or
  • Marketing CEA Tests
  • Major Companies Developing or
  • Marketing Estrogen Receptor Tests
  • Major Companies Developing or
  • Marketing Progesterone Receptor Tests
  • Major Companies Developing or
  • Marketing Ferritin Tests
  • Major Companies Developing or
  • Marketing Gastrin Tests
  • Major Companies Developing or
  • Marketing HCG Tests
  • Major Companies Developing or
  • Marketing Insulin Tests
  • Major Companies Developing or
  • Marketing NSE Tests
  • Major Companies Developing or
  • Marketing Occult Blood Tests
  • Major Companies Developing or
  • Marketing PAP Smear/HPV Tests
  • Major Companies Developing or
  • Marketing PAP Tests
  • Major Companies Developing or
  • Marketing PSA Tests
  • Major Companies Developing or Marketing
  • Lymphocyte Subclassification Tests
  • Biochemical Markers Potential Applications
  • In Cancer Diagnosis
  • Oncogenes Potential Applications
  • In Cancer Diagnosis
  • Major Companies Developing or
  • Marketing Oncogene Tests
  • Growth Factors Potential Applications
  • In Cancer Diagnosis
  • Colony Stimulating Factors Potential
  • Applications in Cancer Diagnosis
  • Lymphokines Potential Applications
  • in Cancer Diagnosis
  • Immunohistochemical Stains Potential
  • Applications in Cancer Diagnosis
Back to Top
전화 문의
F A Q